Prevention · Screening · Early detection

Prostate Cancer Screening: PSA Explained

PSA screening is a preference-sensitive decision. It can identify significant disease but can also lead to overdiagnosis and unnecessary treatment.

Chapter 12 of 16

12 of 16
Choose a chapter

Key facts

  • PSA is prostate-specific, not cancer-specific.
  • A newly raised PSA often needs confirmation and clinical context.
  • Screening does not mean that every cancer found needs immediate treatment.

Recommendations at a glance

These are guideline comparisons, not a personalised prescription. Symptoms and high-risk history take priority over routine screening schedules.

Eligibility, timing and limitations
Guideline / groupAge or eligibilityTest / intervalImportant limitation
USPSTF 201855–69Shared decision before PSABalance benefit against overdiagnosis and procedures
USPSTF 201870+Against routine screeningSymptoms still need evaluation
Increased inherited/family riskIndividual earlier discussionSpecialist planChoose the guideline and interval with the clinician

Choose the right next step

  1. New or concerning symptoms? Arrange diagnostic assessment. Severe bleeding, breathlessness or new neurological weakness needs urgent care.
  2. No symptoms, but previous cancer, precancer or increased inherited risk? Ask for an individual surveillance plan; average-risk intervals may not apply.
  3. No such history? Use this chapter to discuss prevention and, where appropriate, age- and test-specific screening. Lifestyle exposures alone do not establish eligibility for every test.
  4. After testing: Collect the result, complete any referral, and record the next review date. A normal screen does not explain a later symptom.

What PSA means

Prostate-specific antigen is made by prostate tissue. Cancer can raise PSA, but so can benign enlargement, inflammation, infection and recent urinary instrumentation. A single number cannot diagnose cancer. Symptoms such as urinary difficulty can have benign causes but still deserve assessment; screening advice applies to people without symptoms.

Guidelines and shared decisions

USPSTF 2018 supports an individual decision at 55–69 (grade C) and recommends against routine screening at 70 or older (grade D). Specialty-society recommendations may use earlier risk-based testing and different repeat intervals. An individual plan should specify the guideline, prior PSA, health and preferences rather than treating one age threshold as universal.

Who may need earlier discussion?

Strong family history, particularly early or lethal prostate cancer, and pathogenic variants such as BRCA2 can change the approach. Age alone is not enough: general health, life expectancy, prior PSA, personal preferences and willingness to undergo subsequent tests matter. Indian opportunistic screening should be discussed explicitly, not bundled silently into a routine blood panel.

After a raised PSA

Review infection, recent procedures, prior values and other reversible influences. Repeat testing is often appropriate before secondary biomarkers, imaging or biopsy, with timing set by the clinician. Do not self-treat with antibiotics to lower a PSA when infection is not established. PSA density relates PSA to prostate volume and can contribute to risk assessment, but no single cut-off should be used in isolation.

MRI, biopsy and active surveillance

Multiparametric MRI can help identify suspicious areas and guide biopsy decisions. A normal MRI does not exclude every significant cancer; persistent clinical risk may still justify biopsy. Tissue sampling is generally needed to establish diagnosis. Selected low-risk cancers may be monitored with active surveillance, including planned PSA, imaging and sometimes repeat biopsy. Surveillance is organised care, not neglect.

Weighing benefit, harm and practical access

The potential reduction in prostate-cancer death must be balanced against false positives, biopsy complications and treatment-related urinary, sexual and bowel effects. Benefits may take years to emerge. Before testing, ask how an abnormal result would be investigated and whether you would consider those steps. Screening is less likely to help when competing illness markedly limits life expectancy.

Practical steps

  • Ask for a discussion before PSA is added to a screening package.
  • Bring previous results and relevant family history.
  • Arrange urology review for persistent unexplained elevation or concerning symptoms.

Myth and fact

Every PSA above a single threshold means cancer.

False. Interpretation depends on clinical context and further assessment.

Frequently asked questions

Does every diagnosed cancer need surgery?

No. Carefully selected low-risk cancers may be managed with active surveillance.

Can MRI guarantee that biopsy is unnecessary?

No. MRI findings must be interpreted alongside overall risk.

Continue learning

Sources and guideline context